AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas
A Single Arm Phase 2 Study of the Dual mTORC1/mTORC2 Inhibitor AZD2014 Provided on an Intermittent Schedule for Neurofibromatosis 2 Patients With Progressive or Symptomatic Meningiomas
Sponsor: AstraZeneca
A PHASE2 clinical study on Meningioma and Neurofibromatosis 2, this trial is completed. The trial is conducted by AstraZeneca and has accumulated 10 data snapshots since 2016. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jul 2022 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2022 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Aug 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
▶ Show 5 earlier versions
-
Jan 2019 — Aug 2020 [monthly]
Active Not Recruiting PHASE2
-
Jun 2018 — Jan 2019 [monthly]
Active Not Recruiting PHASE2
-
Oct 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Feb 2017 — Oct 2017 [monthly]
Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE2
First recorded
Aug 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
- Massachusetts General Hospital
- United States Department of Defense
For direct contact, visit the study record on ClinicalTrials.gov .